Amgen: Strong growth company with a challenging future

Since it was founded in 1980, Amgen has established itself as a leading global biotechnology company and built increasingly strong human therapeutics brands as well as state of the art manufacturing facilities. This case study analyses the company's recent financial performance, evaluates the strategies that have helped it become a global leader, and explores what the future may hold.

Scope

  • Investigation of Amgen’s success and a detailed analysis of its rise to be one of the most innovative biotechnology companies in the world.
  • Parallel comparisons in terms of R&D, stock market and financial performance to identify its strengths and weaknesses among its peers.
  • Analysis of the challenges that Amgen faces both internally and externally.
  • The case study also focuses on the R&D and acquisition strategy of the company.

Reasons to buy

How did Amgen become the world's leading Biotechnology company?

What are the key challenges the company now faces?

Companies mentioned

None

None

Table of Contents

OVERVIEW

Catalyst

Summary

CONSISTENT GROWTH ACCOMPANIED WITH SIGNIFICANT CHALLENGES

AMGen to Amgen

Rapid growing, profitable multi-billion dollar business

Profitable growth

Reliance on Neulasta and ENBREL ...

OVERVIEW

Catalyst

Summary

CONSISTENT GROWTH ACCOMPANIED WITH SIGNIFICANT CHALLENGES

AMGen to Amgen

Rapid growing, profitable multi-billion dollar business

Profitable growth

Reliance on Neulasta and ENBREL

Dependence on North America

Strong stock market performance

FOCUSED AND WELL-MANAGED R&D

Amgen: An innovative human therapeutics company

Organic growth stimulated by committed R&D investment

Acquisitions continues to reap great results

BOTH INTERNAL AND EXTERNAL CHALLENGES AHEAHD

Challenges within the organization

Inability to produce blockbuster drugs

Litigation settlements hurt Amgen’s financial performance

Difficult external challenges ahead

Problematic acquisition

The rise of Gilead

CONCLUSIONS

Opportunity coincides with challenge for Amgen

APPENDIX

Definitions

Sources

Further Reading

Ask the analyst

About MarketLine

Disclaimer

List of Tables

NA

NA

List of Figures

NA

NA

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports